Tarsus Pharmaceuticals (TARS) Equity Average (2019 - 2026)

Tarsus Pharmaceuticals' Equity Average history runs 8 years deep, the most recent figure standing at $346.2 million for Q1 2026.

• In Q1 2026, Equity Average rose 22.11% year-over-year to $346.2 million; the TTM figure through Mar 2026 stood at $346.2 million (up 22.11% YoY), while the FY2025 annual figure was $284.0 million, up 34.74% from the prior year.
• Equity Average was $346.2 million for Q1 2026 at Tarsus Pharmaceuticals, up from $339.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $346.2 million in Q1 2026 to a low of $158.0 million in Q1 2022.
• Historically, Equity Average has averaged $241.1 million across 5 years, with a median of $231.0 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Equity Average fell 14.79% in 2023, then jumped 64.25% in 2024.
• A 5-year view of Equity Average shows it stood at $197.8 million in 2022, then climbed by 3.82% to $205.3 million in 2023, then advanced by 12.51% to $231.0 million in 2024, then jumped by 46.86% to $339.3 million in 2025, then grew by 2.04% to $346.2 million in 2026.
• The last three Equity Average figures came in at $346.2 million (Q1 2026), $339.3 million (Q4 2025), and $333.8 million (Q3 2025), per Business Quant data.